Contract Biomanufacturing Services Global Market - Forecast to 2025

  • ID: 4375444
  • Report
  • Region: Global
  • 206 Pages
  • IQ4I Research & Consultancy Pvt. Ltd
1 of 5
The Contract Biomanufacturing Global Market is Expected to Grow at Double Digit CAGR to Reach $36.6 Billion by 2025

FEATURED COMPANIES

  • Abbvie
  • Biodextris
  • Crown Biosciences
  • Immunoreagents
  • Menarini Biotech S.R.L
  • Samsung Biologics
  • MORE

The contract biomanufacturing global market is expected to grow at double digit CAGR to reach $36.6 billion by 2025. Biomanufacturing is a widely used term to describe manufacture of biologic molecules for various stages of drug development right from pre-clinical stage to commercial supply. The biologic drug manufacturing is a complex process involving huge capital and sound technical expertise. Many large and small pharmaceutical companies are turning to outsourcing the drug manufacture process to reduce capital investments on capacities and focus more on their core competencies. Contract manufacturing organizations, particularly for R&D and clinical trials, are making product manufacture, more efficient and often less costly. In addition to that, the use of single-use bioreactors is effectively reducing the manufacture facility cost. This option is more viable for smaller and low-funded companies for their in-house candidate product manufacturing needs, whereby, the companies can avoid $50-$150 million facility costs for construction of fixed, dedicated stainless steel bioreactor-based bioprocessing systems and outsource their manufacturing requirements to CMOs which use single-use facilities which typically cost $25-$40 million for commercial manufacture.

There is a continued growth of biopharmaceutical market which is expected to nearly double in next 10 years. This will be a result of continued new product approvals, expansion of indications for current products which include less-developed countries becoming more affluent and increased drug demand of the aging population in the U.S. and other major pharmaceutical markets. Aging populations are at a high risk of developing chronic diseases such as cancer and arthritis and these diseases are being precisely targeted using biopharmaceuticals. Many blockbuster drugs losing their exclusivity are also giving room for many biosimilar (and bio-betters) companies to enter into the world’s biopharmaceuticals market subsequently attracting many CROs, CDMOs, and CMOs to enter into the picture. Hence, there is every reason to assume that future growth in biopharmaceutical outsourcing will continue at a minimum X% in western countries to about X% in Asian countries.

Contract manufacturing market was estimated region wise with segmental revenues for various end user groups such as diagnostics, research reagents and therapeutics. Total available manufacturing capacity was estimated with distinction between GMP vs. non-GMP, in-house vs. CMOs and clinical vs. commercial contract manufacturing. Key developments such as collaborations, capacity expansions and acquisitions were reported and analyzed.

  • In depth assessment of all segments and sub segments of contract biomanufacturing global market
  • Regional analysis of contract biomanufacturing global market
  • Market dynamics for contract manufacturing
  • Market sizing based on end users
  • Emerging trends and strategies
  • Market share analysis of major players in contract manufacturing global market
  • Competitive landscape with regard to capacities for major CMOs
  • CMO service matrix based on type of cell culture techniques, revenues and employee size
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie
  • Biodextris
  • Crown Biosciences
  • Immunoreagents
  • Menarini Biotech S.R.L
  • Samsung Biologics
  • MORE

1 Biologics Contract Manufacturing Global Market
1.1 Executive Summary

2 Market Analysis
2.1 Factors Influencing Market
2.1.1 Drivers and Opportunities
2.1.1.1 Globalization of Outsourcing for Biomanufacturing
2.1.1.2 Increased Funding from Private Investors and Government for Development of Cmos
2.1.1.3 Emergence of Single Use Bioreactors
2.1.1.4 Increasing Biologics Approvals in the Past Year
2.1.1.5 Successful Collaboration and Low Cost for Outsourcing
2.1.2 Restraints and Threats
2.1.2.1 High Requirement for Capital Investments Restraining Many Cmos to Enter the Biologics Space
2.1.2.2 Risk of Product Contamination & Maintaining High Productivity
2.1.2.3 Entry of Large Pharmaceutical Company With Exess Capacity Into the Cmo Market
2.1.2.4 Stringent Regulations and Mandatory Requirement of Cgmp Certifications

3 Contract Biomanufacturing Services
3.1.1 Introduction
3.2 Contract Biomanufacturing, by Process
3.2.1 Biomanufacturing by Mammalian Cell Culture
3.2.2 Biomanufacturing by Microbial Cell Culture
3.2.3 Biomanufacturing by Other Cell Culture
3.3 Contract Biomanufacturing Global Market, by End Users
3.3.1 Contract Biomanufacturing of Diagnostics
3.3.2 Contract Biomanufacturing of Research Reagents
3.3.3 Contract Biomanufacturing of Therapeutics
3.4 Contract Biomanufacturing Global Market, by Region
3.5 Competitive Landscape
3.5.1 Capacity Comparison
3.5.2 Contract Biomanufacturing Global Market Share, by Leading Players
3.6 Company Developments
3.6.1 Merger and Acquisition by Cmos
3.6.2 Collaborations
3.6.3 Capacity Expansions
 
4 Company Profiles
4.1 Abzena Plc
4.1.1 Overview
4.1.2 Financials
4.1.3 Service Portfolio
4.1.4 Key Developments
4.1.5 SWOT Analysis
4.2 Albany Molecular Research Inc
4.2.1 Overview
4.2.2 Financials
4.2.3 Service Portfolio
4.2.4 Key Developments
4.2.5 SWOT Analysis
4.3 Asahi Glass Co. Ltd.
4.3.1 Overview
4.3.2 Financials
4.3.3 Service Portfolio
4.3.4 Key Developments
4.3.5 SWOT Analysis
4.4 Boehringer Ingelheim
4.4.1 Overview
4.4.2 Financials
4.4.3 Service Portfolio
4.4.4 Key Developments
4.4.5 SWOT Analysis
4.5 Catalent Inc.
4.5.1 Overview
4.5.2 Financials
4.5.3 Service Portfolio
4.5.4 Key Developments
4.5.5 SWOT Analysis
4.6 Charles River Laboratories
4.6.1 Overview
4.6.2 Financials
4.6.3 Service Portfolio
4.6.4 Key Developments
4.6.5 SWOT Analysis
4.7 Fujifilm Holdings Corporation
4.7.1 Overview
4.7.2 Financials
4.7.3 Service Portfolio
4.7.4 Key Developments
4.7.5 SWOT Analysis
4.8 Horizon Discovery Group, Plc
4.8.1 Overview
4.8.2 Financials
4.8.3 Service Portfolio
4.8.4 Key Developments
4.8.5 SWOT Analysis
4.9 Innovent Biologics
4.9.1 Overview
4.9.2 Financials
4.9.3 Service Portfolio
4.9.4 Key Developments
4.9.5 SWOT Analysis
4.1 Jhl Biotech Inc.
4.10.1 Overview
4.10.2 Financials
4.10.3 Service Portfolio
4.10.4 Key Developments
4.10.5 SWOT Analysis
4.11 Lonza Group
4.11.1 Overview
4.11.2 Financials
4.11.3 Service Portfolio
4.11.4 Key Developments
4.11.5 SWOT Analysis
4.12 Merck Kgaa
4.12.1 Overview
4.12.2 Financials
4.12.3 Product Portfolio
4.12.4 Key Developments
4.12.5 SWOT Analysis
4.13 Patheon N.V.
4.13.1 Overview
4.13.2 Financials
4.13.3 Service Portfolio
4.13.4 Key Developments
4.13.5 SWOT Analysis
4.14 Proteogenix
4.14.1 Overview
4.14.2 Financials
4.14.3 Service Portfolio
4.14.4 Key Developments
4.14.5 SWOT Analysis
4.15 Rentschler Biotechnologie Gmbh
4.15.1 Overview
4.15.2 Financials
4.15.3 Service Portfolio
4.15.4 Key Developments
4.15.5 SWOT Analysis
4.16 Selexis Sa
4.16.1 Overview
4.16.2 Financials
4.16.3 Service Portfolio
4.16.4 Key Developments
4.16.5 SWOT Analysis
4.17 Syngene International
4.17.1 Overview
4.17.2 Financials
4.17.3 Service Portfolio
4.17.4 Key Developments
4.17.5 SWOT Analysis
4.18 Wuxi Apptec
4.18.1 Overview
4.18.2 Financials
4.18.3 Service Portfolio
4.18.4 Key Developments
4.18.5 SWOT Analysis

List of Tables
Table 1 Capacity Comparison of Contract Manufacturing Organizations V’S In-House Capacities (L)
Table 2 Contract Biomanufacturing Global Market Revenue, by Stage ($Bn)
Table 3 Contract Manuacturing Organizations Capacity, by Process (L)
Table 4 Contract Biomanufacturing Global Market Revenue, by Process ($Bn)
Table 5 Anticancer Drugs Synthesized in Microbial Cell Culture
Table 6 Biomanufacturing Outsourcing Global Market by End Users ($Bn)
Table 7 Second Generation Protein Therapeutics
Table 8 Therapeutic Vaccines in Pipeline
Table 9 Biomanufacturing Outsourcing Global Market by Region ($Bn)
Table 10 Company Comparison Matrix, by Manufacturing Capability
Table 11 Mergers and Acquitions (2015-2017)
Table 12 Collaborations (2016-2017)
Table 13 Capacity Expansions (2016-2017)
Table 14 Abzena Plc: Total Revenue and R&D Expenses (2014-2016) ($Mn)
Table 15 Abzena Plc: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 16 Albany Molecular Research Inc: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 17 Albany Molecular Research Inc: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 18 Albany Molecular Research: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 19 Asahi Glass Co. Ltd.: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 20 Asahi Glass Co. Ltd. : Total Revenue, by Segments, (2014-2016) ($Mn)
Table 21 Boehringer Ingelheim: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 22 Boehringer Ingelheim: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 23 Boehringer Ingelheim: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 24 Catalent Inc: Total Revenue and R&D Expenses (2014-2016) ($Mn)
Table 25 Catalent Inc: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 26 Catalent Inc: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 27 Charles River Laboratories: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 28 Charles River Laboratories: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 29 Charles River Laboratories: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 30 Fujifilm Holdings Corporation : Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 31 Fujifilm Holdings Corporation : Total Revenue, by Segments (2014-2016) ($Mn)
Table 32 Fujifilm Holdings Corporation : Total Revenue, by Geography (2014-2016) ($Mn)
Table 33 Horizon Discovery Group: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 34 Horizon Discovery Group: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 35 Horizon Discovery Group: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 36 Lonza Group: Total Revenue and R&D Expenses (2014-2016) ($Mn)
Table 37 Lonza Group: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 38 Lonza Group: Total Revenue, by Geography (2014-2016) ($Mn)
Table 39 Merck Kgaa: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 40 Merck Kgaa: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 41 Merck Kgaa: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 42 Patheon N.V.: Total Revenue and R&D Expenses (2014-2016) ($Mn)
Table 43 Patheon N.V.: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 44 Syngene International: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 45 Syngene International: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 46 Wuxi Apptec: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
 
List of Figures
Figure 1 Market Dynamics
Figure 2 Industry Pipeline for Small Molecule V’S Biologics
Figure 3 Global Manufacturing Capacity, Cgmp V’S Non-Cgmp, Inhouse V’S Cmo, 2016
Figure 4 Capacity Utilization of Contract Manufacturing Organizations, by Stage (L)
Figure 5 Contract Biomanufacturing Global Market Revenue, by Stage ($Bn)
Figure 6 Capacity Comparison of Mammalian, Microbial and Other Culture Systems (L)
Figure 7 Contract Biomanufacturing Global Market Revenue, by Process ($Bn)
Figure 8 Bio-Manufacturing Outsourcing Global Market, by End Users ($Bn)
Figure 9 Outlook of Biologics Cmo Global Market, by Region ($Bn) and Production in Metric Tons, 2016
Figure 10 Capacity Composition of Top 10 Contract Manufacturing Organizations (L)
Figure 11 Market Share Analysis by Contract Manufacturing Major Players, 2016
Figure 12 Company Developments (2016-2017)
Figure 13 Overview: Abzena Plc
Figure 14 SWOT: Abzena Plc
Figure 15 Overview: Albany Molecular Research Institute
Figure 16 SWOT: Albany Molecular Research, Inc
Figure 17 Overview: Asahi Glass Co. Ltd.
Figure 18 SWOT: Asahi Glass Co. Ltd.
Figure 19 Overview: Boehringer Ingelheim
Figure 20 SWOT: Boehringer Ingelheim
Figure 21 Overview: Catalent Inc.
Figure 22 SWOT: Catalent Inc.
Figure 23 Overview: Charles River Laboratories
Figure 24 SWOT: Charles River Laboratories
Figure 25 Overview: Fujifilm Holdings Corporation
Figure 26 SWOT: Fujifilm Diosynth Biotechnologies
Figure 27 Overview: Horizon Discovery Group, Plc
Figure 28 SWOT: Horizon Discovery Group, Plc
Figure 29 SWOT: Innovent Biologics
Figure 30 SWOT: Jhl Biotech Inc.
Figure 31 Overview: Lonza Group
Figure 32 SWOT: Lonza Group
Figure 33 Overview: Merck Kgaa
Figure 34 SWOT: Merck Kgaa
Figure 35 Overview: Patheon N.V.
Figure 36 SWOT: Patheon N.V.
Figure 37 SWOT: Proteogenix
Figure 38 SWOT: Rentschler Biotechnologie
Figure 39 SWOT: Selexis Sa
Figure 40 Overview: Syngene International
Figure 41 SWOT: Syngene International
Figure 42 SWOT: Wuxi Apptec

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbvie
  • Abnova
  • Abzena
  • Affinity Lifesciences
  • Agc Asahi Glass (Cmc Biologics)
  • Alexion Pharmaceuticals
  • Anogen
  • Avid Bioservices
  • Bharat Biotech Ltd
  • Binex Co. Ltd.
  • Bioconnect Life Sciences
  • Biodextris
  • Biogen
  • Bioreliance Safc
  • Boehringer Ingelheim
  • Cadila Healthcare Ltd
  • Catalent Inc.
  • Celltrion
  • Charles River Laboratories
  • Cobra Biologics
  • Cook Pharmica
  • Covance Research Products
  • Crown Biosciences
  • Cytovance Biologics
  • Dendreon Corporation
  • Diatheva
  • Envigo
  • Eurofins
  • Europa Bioproducts
  • Evotec
  • Fapon
  • Fujifilm Diosynth Biotechnologies
  • Gtp Technology
  • Immunoreagents
  • Inno Biologics
  • Innovent Bio
  • Intas Pharmaceuticals
  • Jhl Biotech
  • Jsr Corporation (Kbi Biopharma)
  • Jubilant Hollisterstier
  • Kemwell Biopharma
  • Lake Pharma
  • Lampire Biological Laboratories
  • Lonza
  • Luina Bio
  • Menarini Biotech S.R.L
  • Merck Gmbh
  • Miltenyi Biotech Gmbh
  • Novasep
  • Omnia Biologics
  • Paragon Bioservices
  • Patheon
  • Premas Biotech Pvt Ltd
  • Proteogenix
  • Rentschler Biotechnologie
  • Samsung Biologics
  • Sandoz Gmbh
  • Scripps Laboratories
  • Serum Institute of India
  • Syngene
  • Therapure Biopharma
  • Toyobo Co. Ltd.
  • U-Protein Express Bv
  • Vifor Pharma Ltd
  • Waisman Clinical Biomanufacturing
  • Wuxi Apptec
  • Xcellerex
  • Zymeworks Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll